Article Text

Download PDFPDF

Safety and survival data in patients with idiopathic pulmonary fibrosis treated with nintedanib: pooled data from six clinical trials
  1. Lisa Lancaster1,
  2. Bruno Crestani2,
  3. Paul Hernandez3,
  4. Yoshikazu Inoue4,
  5. Daniel Wachtlin5,
  6. Lazaro Loaiza6,
  7. Manuel Quaresma6,
  8. Susanne Stowasser6 and
  9. Luca Richeldi7
  1. 1Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA
  2. 2APHP, Service de Pneumologie, Hôpital Bichat, Paris, France; Université Paris Diderot, Paris, France
  3. 3QEII Health Sciences Centre, Halifax, Nova Scotia, Canada
  4. 4Diffuse Lung Diseases and Respiratory Failure, National Hospital Organization Kinki-Chuo Chest Medical Center, Osaka, Japan
  5. 5Boehringer Ingelheim Pharma GmbH & Co KG, Ingelheim am Rhein, Germany
  6. 6Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany
  7. 7Fondazione Policlinico A Gemelli IRCCS, Università Cattolica del Sacro Cuore, Rome, Italy
  1. Correspondence to Dr Lisa Lancaster; lisa.lancaster{at}vanderbilt.edu

Footnotes

  • Contributors All authors were involved in planning the analyses, in the interpretation of data and in drafting the manuscript.

  • Funding The trials that provided data for these analyses were funded by Boehringer Ingelheim.

  • Competing interests LLa has served on advisory boards for Genentech, Global Blood Therapeutics, Boehringer Ingelheim, Veracyte, Theravance, Magnolia Therapeutics, Galapagos and Bellerophon; has provided disease state education for Genentech and Boehringer Ingelheim; has served as a principal investigator in clinical trials in IPF and other ILDs for Genentech, Global Blood Therapeutics, Celgene, FibroGen, Stromedix, Veracyte, Afferent, Merck, Bellerophon, Novartis, Galapagos, Galecto, the National Institutes of Health and Boehringer Ingelheim. BC has received grants from Apellis and MedImmune; grants and personal fees from Boehringer Ingelheim and Roche; and personal fees from AstraZeneca and Sanofi. PH has served on advisory boards for Actelion, AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Teva and Trudell; served as a principal investigator in clinical trials in IPF for Boehringer Ingelheim and Prometic; and provided disease state education in IPF/ILDs for Boehringer Ingelheim and Roche. YI has served on advisory boards for Boehringer Ingelheim and reports lecture and advisory fees from Boehringer Ingelheim, Shionogi & Co, Ltd, Takeda, Nobel Pharma, Novartis, Serendex, Bayer, Chugai and Daiichi Sankyo. LR has served on advisory boards for Anthera, Asahi-Kasei, AstraZeneca, Bayer, Boehringer Ingelheim, Biogen Idec, FibroGen, GlaxoSmithKline, ImmuneWorks, InterMune, MedImmune, PatientsLikeMe, Promedior, Roche, Sanofi-Aventis, Takeda and UCB; received grants from InterMune, the Italian Ministry of Health, the National Drug Agency (Italy), the National Research Council (Italy) and Roche; and received speaker fees from Boehringer Ingelheim, Cipla, InterMune and Roche. DW, LLo, MQ and SS are employees of Boehringer Ingelheim.

  • Patient consent for publication Not required.

  • Ethics approval All clinical trial protocols were approved by an independent ethics committee or institutional review board at every participating institution.

  • Provenance and peer review Not commissioned; externally peer reviewed.

  • Data sharing statement Data are available uponon request. A request can be submitted via https://trials.boehringer-ingelheim.com/trial_results/clinical_submission_documents.html.

View Full Text

Statistics from Altmetric.com

Footnotes

  • Contributors All authors were involved in planning the analyses, in the interpretation of data and in drafting the manuscript.

  • Funding The trials that provided data for these analyses were funded by Boehringer Ingelheim.

  • Competing interests LLa has served on advisory boards for Genentech, Global Blood Therapeutics, Boehringer Ingelheim, Veracyte, Theravance, Magnolia Therapeutics, Galapagos and Bellerophon; has provided disease state education for Genentech and Boehringer Ingelheim; has served as a principal investigator in clinical trials in IPF and other ILDs for Genentech, Global Blood Therapeutics, Celgene, FibroGen, Stromedix, Veracyte, Afferent, Merck, Bellerophon, Novartis, Galapagos, Galecto, the National Institutes of Health and Boehringer Ingelheim. BC has received grants from Apellis and MedImmune; grants and personal fees from Boehringer Ingelheim and Roche; and personal fees from AstraZeneca and Sanofi. PH has served on advisory boards for Actelion, AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Teva and Trudell; served as a principal investigator in clinical trials in IPF for Boehringer Ingelheim and Prometic; and provided disease state education in IPF/ILDs for Boehringer Ingelheim and Roche. YI has served on advisory boards for Boehringer Ingelheim and reports lecture and advisory fees from Boehringer Ingelheim, Shionogi & Co, Ltd, Takeda, Nobel Pharma, Novartis, Serendex, Bayer, Chugai and Daiichi Sankyo. LR has served on advisory boards for Anthera, Asahi-Kasei, AstraZeneca, Bayer, Boehringer Ingelheim, Biogen Idec, FibroGen, GlaxoSmithKline, ImmuneWorks, InterMune, MedImmune, PatientsLikeMe, Promedior, Roche, Sanofi-Aventis, Takeda and UCB; received grants from InterMune, the Italian Ministry of Health, the National Drug Agency (Italy), the National Research Council (Italy) and Roche; and received speaker fees from Boehringer Ingelheim, Cipla, InterMune and Roche. DW, LLo, MQ and SS are employees of Boehringer Ingelheim.

  • Patient consent for publication Not required.

  • Ethics approval All clinical trial protocols were approved by an independent ethics committee or institutional review board at every participating institution.

  • Provenance and peer review Not commissioned; externally peer reviewed.

  • Data sharing statement Data are available uponon request. A request can be submitted via https://trials.boehringer-ingelheim.com/trial_results/clinical_submission_documents.html.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.